About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2024№11
Interdisciplinary discussion on the potential...

Interdisciplinary discussion on the potential use of a subcutaneous contraceptive implant in patients with chronic diseases

DOI
https://dx.doi.org/10.18565/aig.2024.288

Yarmolinskaya M.I., Nedogoda S.V., Avdeev S.N., Tsareva N.A., Andreeva E.N., Samarina A.V., Amelina E.L., Gubonina I.V., Klimenchenko N.I.

1) D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, St. Petersburg, Russia; 2) I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, St. Petersburg, Russia; 3) Volgograd State Medical University, Ministry of Health of Russia, Volgograd, Russia; 4) I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia; 5) National Medical Research Centre for Endocrinology, Ministry of Health of Russia, Moscow, Russia; 6) Russian University of Medicine, Ministry of Health of Russia, Moscow, Russia; 7) Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, St. Petersburg, Russia; 8) Centre for Prevention and Control of AIDS and Infectious Diseases, St. Petersburg, Russia; 9) Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia, Moscow, Russia; 10) Scandinavia Clinic (AVA-PETER LLC), St. Petersburg, Russia; 11) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

There is a need for greater awareness of the use of modern contraceptive methods in today’s medical practice. This can be due to the low level of public knowledge about contraceptive methods and to the fact that contraception remains within the scope of obstetricians and gynecologists, who consult on the choice of contraceptive method, prescribe a contraceptive and then carry out routine follow-up. However, there are a number of chronic somatic diseases in which an unplanned pregnancy is a threat to the life and health of both the woman and her future child. The issue of contraceptive use and the assessment of drug interactions may be overlooked when patients with a variety of chronic conditions are referred to other specialists and prescribed treatment for their primary diagnosis. The panel discusses the potential use of the subcutaneous contraceptive implant releasing etonogestrel in patients with a variety of chronic diseases, including cardiovascular, pulmonary and endocrine pathologies, immune-mediated and orphan diseases, chronic viral infections and tuberculosis. The etonogestrel implant is a highly effective long-acting reversible hormonal contraceptive option and is the method of choice for women with chronic medical conditions that may limit the use of the estrogen component.
Conclusion: Interdisciplinary collaboration between obstetricians and gynecologists and other specialists is necessary for choosing the best contraceptive method for patients with chronic diseases. Interdisciplinary documents (methodological and/or clinical guidelines) on the use of contraception in specific groups of patients with contraindications to pregnancy could be developed in addition to the current National Medical Eligibility Criteria for Contraceptive Use (2023) and the draft clinical guidelines ‘Contraception. Contraceptive Surveillance’ (2024), which would expand relevant information on contraception for various medical specialists (including cardiologists, endocrinologists, pulmonologists, rheumatologists, infectious disease specialists, and others).

Authors' contributions: Yarmolinskaya M.I., Nedogoda S.V., Avdeev S.N., Tsareva N.A., Andreeva E.N., Samarina A.V., Amelina E.L., Gubonina I.V., Klimenchenko N.I. – concept and design, writing the text, editing.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Yarmolinskaya M.I., Nedogoda S.V., Avdeev S.N., Tsareva N.A., Andreeva E.N., Samarina A.V., Amelina E.L., Gubonina I.V., Klimenchenko N.I. Interdisciplinary discussion on the potential use of 
a subcutaneous contraceptive implant in patients with chronic diseases.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (11): 40-55 (in Russian)
https://dx.doi.org/10.18565/aig.2024.288

Keywords

long-acting progestin-only contraception
subcutaneous etonogestrel-releasing implant
chronic diseases
multidisciplinary approach
Full text (in Russian)

References

  1. Zolna M., Lindberg L. Unintended pregnancy: incidence and outcomes among young adult unmarried women in the United States, 2001 and 2008. New York: Guttmacher Institute; 2012.
  2. WНО. Safe and unsafe induced abortion. Global and regional levels in 2008 and trends during 1995–2008. Information Sheet. 2012.
  3. Brown S.S., Eisenberg L., eds. The best intentions: unintended pregnancy and the well-being of children and families. National Academic Press; 1995.
  4. Cheng D., Schwarz E.B., Douglas E., Horon I. Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors. Contraception. 2009; 79(3): 194-8. https://dx.doi.org/10.1016/j.contraception.2008.09.009.
  5. Trussell J., Henry N., Hassan F., Prezioso A., Law A., Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception. 2013; 87(2): 154-61. https://dx.doi.org/10.1016/j.contraception.2012.07.016.
  6. Hassan F. Cost of unintended pregnancy in the United Kingdom: a role for increased use of long-acting reversible contraceptive methods. ISPOR 15th Annual European Congress Berlin, Germany, 3–7 November 2012; Abstract No. 39708.
  7. Сухих Г.Т., Прилепская В.Н., ред. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5-е издание, 2015». М.; 2023. [Sukhikh G.T., Prilepskaya V.N., ed. National medical criteria for the acceptability of contraception methods. Adapted document "WHO Medical eligibility criteria for contraceptive use, 5th edition, 2015". Moscow; 2023. (in Russian)].
  8. Министерство здравоохранения Российской Федерации. Проект клинических рекомендаций «Контрацепция. Наблюдение за применением противозачаточных средств». 2024. 48 с. [Ministry of Health of the Russian Federation. Project of Clinical guidelines "Contraception. Monitoring the use of contraceptives". 2024. 48 p.(in Russian)].
  9. Исследование мнения пациенток в отношении методов контрацепции, Ipsos, октябрь 2020. [Patient Opinion Survey on Contraceptive Methods, Ipsos, October 2020. (in Russian)].
  10. ACOG Committee Opinion on Gynecologic Practice Guideline. Obstet. Gynecol. 2015; 126: e44-8.
  11. Curtis K.M., Nguyen A.T., Tepper N.K., Zapata L.B., Snyder E.M., Hatfield-Timajchy K. et al.; Contributors. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recomm. Rep. 2024; 73(3): 1-77. https://dx.doi.org/https://dx.doi.org/10.15585/mmwr.rr7303a1.
  12. NICE Long-Acting Reversible Contraception Clinical Guideline. Available at: https://www.nice.org.uk/guidance/cg30/resources/longacting-reversible-contraception-pdf-975379839685 (Accessed November 22, 2024).
  13. American Academy of Pediatrics Policy Statement 2014. Available at: HYPERLINK "http://www.pediatrics.org/cgi/doi/10.1542/peds.2014-2299"www.pediatrics.org/cgi/doi/10.1542/peds.2014-2299 (Accessed November 22, 2024).
  14. Winner B., Peipert J.F., Zhao Q., Buckel C., Madden T., Allsworth J.E. et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012; 366(21): 1998-2007. https://dx.doi.org/10.1056/NEJMoa1110855.
  15. Инструкция по медицинскому применению препарата Импланон НКСТ®. РУ ЛП-№(004826)-(РГ-RU) от 11.03.2024 [Instructions for medical use of Implanon NKST®. RU LP-No. (004826)-(RG-RU) dated 11.03.2024(in Russian)].
  16. Díaz S., Pavez M., Moo-Young A.J., Bardin C.W., Croxatto H.B. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception. 1991; 44(4): 393-408. https://dx.doi.org/10.1016/0010-7824(91)90030-j.
  17. Wenzl R., van Beek A., Schnabel P., Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception. 1998; 58(5): 283-8. https://dx.doi.org/10.1016/s0010-7824(98)00110-3.
  18. Beerthuizen R., van Beek A., Massai R., Mäkäräinen L., Hout J., Bennink H.C. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum. Reprod. 2000; 15(1): 118-22. https://dx.doi.org/10.1093/humrep/15.1.118.
  19. Mansour D., Korver T., Marintcheva-Petrova M., Fraser I.S. The effects of Implanon on menstrual bleeding patterns. Eur. J. Contracept. Reprod. Health Care. 2008; 13 Suppl 1: 13-28. https://dx.doi.org/10.1080/13625180801959931.
  20. Singh S.S., Calaf Alsina J., Vannuccini S., Koga K., Lopes Silva-Filho A., Yang X. et al. Clinical perspectives on the menstrual pictogram for the assessment of heavy menstrual bleeding. Hum. Reprod. Open. 2022; 2022(4): hoac048. https://dx.doi.org/10.1093/hropen/hoac048.
  21. Dou W., Huang Y., Liu X., Huang C., Huang J., Xu B. et al. Associations of oral contraceptive use with cardiovascular disease and all-cause death: evidence from the UK Biobank Cohort Study. J. Am. Heart Assoc. 2023; 12(16): e030105. https://dx.doi.org/10.1161/JAHA.123.030105.
  22. Roach R.E.J., Helmerhorst F.M., Lijfering W.M., Stijnen T., Algra A., Dekkers O.M. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015; 2015(8): CD011054. https://dx.doi.org/10.1002/14651858.CD011054.pub2.
  23. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1997; 349(9060): 1202-9.
  24. Ge S., Tao X., Cai L., Deng X., Hwang M., Wang C. Associations of hormonal contraceptives and infertility medications on the risk of venous thromboembolism, ischemic stroke, and cardiovascular disease in women. J. Investig. Med. 2019; 67(4): 729-35. https://dx.doi.org/10.1136/jim-2018-000750.
  25. Graff-Iversen S., Hammar N., Thelle D.S., Tonstad S. Use of oral contraceptives and mortality during 14 years' follow-up of Norwegian women. Scand. J. Public Health. 2006; 34(1): 11-6. https://dx.doi.org/10.1080/14034940510032239.
  26. Victory R., D'Souza C., Diamond M.P., McNeeley S.G., Vista‐Deck D., Hendrix S. Adverse cardiovascular disease outcomes are reduced in women with a history of oral contraceptive use: Results from the Women's Health Initiative Database. Fertil. Steril. 2004; 82(2): S52-S53. https://dx.doi.org/10.1016/j.fertnstert.2004.07.135.
  27. Belail Hammad W.A., Gupta N., Konje J.C. An overview of contraception in women with obesity. Best Pract. Res. Clin. Obstet. Gynaecol. 2023; 91: 102408. https://dx.doi.org/10.1016/j.bpobgyn.2023.102408.
  28. Lopez L.M., Grimes D.A., Chen M., Otterness C., Westhoff C., Edelman A. et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst. Rev. 2016; 2016(8): CD008452. https://dx.doi.org/10.1002/14651858.CD008452.pub4.
  29. Cosmi B, Legnani C, Libra A, Palareti G. D-Dimers in diagnosis and prevention of venous thrombosis: recent advances and their practical implications. Pol. Arch. Intern. Med. 2023; 133(11): 16604. https://dx.doi.org/10.20452/pamw.16604.
  30. Cameron N.A., Blyler C.A., Bello N.A. Oral contraceptive pills and hypertension: a review of current evidence and recommendations. Hypertension. 2023; 80(5): 924-35. https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.20018.
  31. Lindley K.J., Bairey Merz C.N., Davis M.B., Madden T., Park K., Bello N.A.; American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group. Contraception and Reproductive Planning for Women With Cardiovascular Disease: JACC Focus Seminar 5/5. J. Am. Coll. Cardiol. 2021; 77(14): 1823-34. https://dx.doi.org/10.1016/j.jacc.2021.02.025.
  32. Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart. J. 2016; 37(1): 67-119. https://dx.doi.org/10.1093/eurheartj/ehv317.
  33. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M. et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022; 43(38): 3618-731. https://dx.doi.org/10.1093/eurheartj/ehac237.
  34. Olschewski A., Berghausen E.M., Eichstaedt C.A., Fleischmann B.K., Grünig E., Grünig G. et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int. J. Cardiol. 2018; 272S: 4-10. https://dx.doi.org/10.1016/j.ijcard.2018.09.070.
  35. Humbert M., Guignabert C., Bonnet S., Dorfmüller P., Klinger J.R., Nicolls M.R. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019; 53(1): 1801887. https://dx.doi.org/10.1183/13993003.01887-2018.
  36. Авдеев С.Н., Барбараш О.Л., Баутин А.Е., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С., Горбачевский С.В., Данилов Н.М., Еременко А.А., Мартынюк Т.В., Моисеева О.М., Саидова М.А., Сергиенко В.Б., Симакова М.А., Стукалова О.В., Чазова И.Е., Чернявский А.М., Шалаев С.В., Шмальц А.А., Царева Н.А. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(12): 4683. [Avdeev S.N., Barbarash O.L., Bautin A.E., Volkov A.V., Veselova T.N., Galyavich A.S., Goncharova N.S., Gorbachevsky S.V., Danilov N.M., Eremenko A.A., Martynyuk T.V., Moiseeva O.M., Saidova M.A., Sergienko V.B., Simakova M.A., Stukalova O.V.,Chazova I.E., Chernyavsky A.M., Shalaev S.V., Shmalts A.A., Tsareva N.A. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021; 26(12): 4683. (in Russian)]. https://dx.doi.org/10.15829/1560-4071-2021-4683.
  37. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых (клинические рекомендации). Грудная и сердечно-сосудистая хирургия. 2017; 59(2): 135-47. [Bokeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart defects in adults (clinical recommendation). Thoracic and Cardiovascular Surgery. 2017; 59(2): 135-47. (in Russian)].
  38. Волков А.В., Мартынюк Т.В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани: современное состояние проблемы. Научно-практическая ревматология. 2018; 56(4): 474-85. [Volkov A.V., Martynyuk T.V. Pulmonary arterial hypertension in systemic connective tissue diseases: current state of the problem. Scientific and Practical Rheumatology. 2018; 56(4): 474-85. (in Russian)].
  39. Galiè N., Channick R.N., Frantz R.P., Grünig E., Jing Z.C., Moiseeva O. et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur. Respir. J. 2019; 53(1): 1801889. https://dx.doi.org/10.1183/13993003.01889-2018.
  40. Simonneau G., Montani D., Celermajer D.S., Denton C.P., Gatzoulis M.A., Krowka M. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019; 53(1): 1801913. https://dx.doi.org/10.1183/13993003.01913-2018.
  41. Авдеев С.Н. Легочная гипертензия. Руководство для врачей (2-е издание). М.: ГЭОТАР-Медиа; 2019. 604 с. [Avdeev S.N. Pulmonary hypertension. Manual for doctors (2nd ed.). Moscow: GEOTAR-Media; 2019. 604 p.(in Russian)].
  42. Nathan S.D., Barbera J.A., Gaine S.P., Harari S., Martinez F.J., Olschewski H. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur. Respir. J. 2019; 53(1): 1801914. https://dx.doi.org/10.1183/13993003.01914-2018.
  43. Simonneau G., Torbicki A., Dorfmüller P., Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 2017; 26(143): 160112. https://dx.doi.org/10.1183/16000617.0112-2016.
  44. Cheron C., McBride S.A., Antigny F., Girerd B., Chouchana M., Chaumais M.C. et al. Sex and gender in pulmonary arterial hypertension. Eur. Respir. Rev. 2021; 30(162): 200330. https://dx.doi.org/10.1183/16000617.0330-2020.
  45. Barańska-Pawełczak K., Wojciechowska C., Jacheć W. Pregnancy in patients with pulmonary arterial hypertension in light of new ESC Guidelines on Pulmonary Hypertension. Int. J. Environ. Res. Public Health. 2023; 20(5): 4625. https://dx.doi.org/10.3390/ijerph20054625.
  46. Teng Y., Zong L., Ding J., Wu M., Li X. Management of pulmonary arterial hypertension: before, during and after pregnancy. Int. J. Cardiol. Cardiovasc. Risk Prev. 2024; 21: 200252. https://dx.doi.org/10.1016/j.ijcrp.2024.200252.
  47. Регистр пациентов ECFS. Ежегодный отчет о данных. 2021. Доступно по: https://www.ecfs.eu/sites/default/files/Annual%20Report_2021_09Jun2023.pdf [ECFS Patient Registry. Annual Data Report. 2021. Available at: https://www.ecfs.eu/sites/default/files/Annual%20Report_2021_09Jun2023.pdf(in Russian)].
  48. Воронкова А.Ю., Амелина Е.Л., Каширская Н.Ю. и др., ред. Регистр пациентов с муковисцидозом в Российской Федерации 2022 год. М.: ИД «МЕДПРАКТИКА-М»; 2024. 68 с. [Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu. et al., ed. Register of patients with cystic fibrosis in the Russian Federation. 2022. M.: Publishing House "MEDPRAKTIKA-M"; 2024. 68 p. (in Russian)].
  49. Фонд борьбы с муковисцидозом. Правильное питание во время беременности. Доступно по: www.cff.org/managing-cf/eating-well-during-your-pregnancy [Cystic Fibrosis Foundation (cff.org). Eating Well During Your Pregnancy. Available at: www.cff.org/managing-cf/eating-well-during-your-pregnancy].
  50. Heltshe S.L., Godfrey E.M., Josephy T., Aitken M.L., Taylor-Cousar J.L. Pregnancy among cystic fibrosis women in the era of CFTR modulators. J. Cyst. Fibros. 2017; 16(6): 687-94. https://dx.doi.org/10.1016/j.jcf.2017.01.008.
  51. Montemayor K., Tullis E., Jain R., Taylor-Cousar J.L. Management of pregnancy in cystic fibrosis. Breathe (Sheff). 2022; 18(2): 220005. https://dx.doi.org/10.1183/20734735.0005-2022.
  52. Roe A.H., Traxler S.A., Hadjiliadis D., Sammel M.D., Schreiber C.A. Contraceptive choices and preferences in a cohort of women with cystic fibrosis. Respir. Med. 2016; 121: 1-3. https://dx.doi.org/10.1016/j.rmed.2016.10.012.
  53. Curtis K.M., Tepper N.K., Jatlaoui T.C., Berry-Bibee E., Horton L.G., Zapata L.B. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm. Rep. 2016; 65(3): 1-103. https://dx.doi.org/10.15585/mmwr.rr6503a1.
  54. Kernan N.G., Alton E.W., Cullinan P., Griesenbach U., Bilton D. Oral contraceptives do not appear to affect cystic fibrosis disease severity. Eur. Respir. J. 2013; 41(1): 67-73. https://dx.doi.org/10.1183/09031936.00018712.
  55. Dugré N., Choksi N., Kirkwood J. Etonogestrel implant effectiveness. Can. Fam. Physician. 2022; 68(8): 594. https://dx.doi.org/10.46747/cfp.6808594.
  56. Inal M.M., Yildirim Y., Ertopcu K., Avci M.E., Ozelmas I., Tinar S. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up). Eur. J. Contracept. Reprod. Health Care. 2008; 13(3): 238-42. https://dx.doi.org/10.1080/13625180802075315.
  57. Hernandez-Juarez J., Garcia-Latorre E.A., Moreno-Hernandez M., Moran-Perez J.F., Rodriguez-Escobedo M.A., Cogque-Hernandez G. et al. Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study. Reprod. Health. 2014; 11: 33. https://dx.doi.org/10.1186/1742-4755-11-33.
  58. Moreira I.F.A., Bianchini M.P., Moreira G.R.C., Almeida A.M., Rezende B.A.Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study. BMC Womens Health. 2020; 20(1): 240. https://dx.doi.org/10.1186/s12905-020-01107-1.
  59. Насонов Е.Л., Александрова Е.Н., Новиков А.А. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015; 70(2): 169-82. [Nasonov E.L., Aleksandrova E.N., Novikov A.A. Autoimmune Rheumatic Diseases – Problems of Immunopathology and Personalized Treatment. Annals of the Russian Academy of Medical Sciences. 2015; 70(2): 169-82. (in Russian)]. https://dx.doi.org/10.15690/vramn.v70i2.1310.
  60. de Lima-Karagiannis A., Zelinkova-Detkova Z., van der Woude C.J. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am. J. Gastroenterol. 2016; 111(9): 1305-12. https://dx.doi.org/10.1038/ajg.2016.254.
  61. Hunter-Greaves T., Medley-Singh N., Tate N., McDaniel A., Simms-Stewart D., Rattray C. Contraceptive practices in women with chronic medical conditions. 2021; 41(4): 626-30. https://dx.doi.org/10.1080/01443615.2020.1788522.
  62. Tavernier N., Fumery M., Peyrin-Biroulet L., Colombel J.F., Gower-Rousseau C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013; 38(8): 847-53. https://dx.doi.org/10.1111/apt.12478.
  63. Sammaritano L.R., Bermas B.L., Chakravarty E.E., Chambers C., Clowse M.E.B., Lockshin M.D. et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020; 72(4): 529-56. https://dx.doi.org/10.1002/art.41191.
  64. 2020 ACR Reproductive Health in Rheumatic and Musculoskeletal Diseases Guideline Recommendation Tables with Strength of Evidence Rating. Available at: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt83dd1ceb866821c9/6331cfd0de1e8c340e578bd9/reproductive-health-guideline-appendix-7-recommendation-tables-2020.pdf.
  65. Loutfy M., Johnson M., Walmsley S., Samarina A., Vasquez P., Hao-Lan H. et al. The association between HIV disclosure status and perceived barriers to care faced by women living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/Canada. AIDS Patient Care STDS. 2016; 30(9): 435-44. https://dx.doi.org/10.1089/apc.2016.0049.
  66. Johnson M., Samarina A., Xi H., Valdez Ramalho Madruga J., Hocqueloux L., Loutfy M. et al. Barriers to access to care reported by women living with HIV across 27 countries/ AIDS Patient Care and STDs. 2015; 27(10): 1220-30. https://dx.doi.org/10.1080/09540121.2015.1046416.
  67. End Inequalities. End AIDS. Global AIDS Strategy 2021-2026, UNAIDS, Geneva; 2021. 100p. Available at: https://www.unaids.org/en/Global-AIDS-Strategy-2021-2026
  68. Мозалева О.Л., Самарина А.В. Социально-демографические и эпидемиологические характеристики ВИЧ-инфицированных беременных женщин в Санкт-Петербурге как фактор риска перинатальной передачи ВИЧ. ВИЧ-инфекция и иммуносупрессии. 2019; 11(3): 7-15. [Mozaleva O.L., Samarina A.V. Demographic and epidemiological characteristics of the HIV-infected pregnant women in Saint-Petersburg. HIV Infection and Immunosuppressive Disorders. 2019;11(3):7-15. (in Russian)]. https://dx.doi.org/10.22328/2077-9828-2019-11-3-7-15.
  69. Whiteman M.K., Jeng G., Samarina A., Akatova N., Martirosyan M., Kissin D.M. et al. Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Contraception. 2016; 93 (1): 17-24. https://dx.doi.org/10.1016/j.contraception.2015.07.003.
  70. Morrison C.S., Hofmeyr G.J., Thomas K.K., Rees H., Philip N., Palanee-Phillips T. et al. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on early HIV disease progression. AIDS Res. Hum. Retroviruses. 2020; 36(8): 632-40. https://dx.doi.org/10.1089/AID.2020.0015.
  71. Whiteman M.K., Kissin D.M., Samarina A., Curtis K.M., Akatova N., Marchbanks P.A. et al. Determination of contraceptive choice among women with HIV. AIDS. 2009; 23(Suppl 1): S47-54. https://dx.doi.org/10.1097/01.aids.0000363777.76129.b4.
  72. Критерии приемлемости контрацепции ВОЗ; 2015. [WHO. Medical Eligibility Criteria for Contraceptive Use. 3rd edition. Geneva: WHO; 2015. Available at: https://www.who.int/reproductivehealth/publications/mec/index.htm]
  73. Самарина А.В., Мозалева О.Л., Мартиросян М.М., Скрябнева Т.С., Шамаева Н.С., Филатова М.П. Применение подкожного контрацептивного имплантата у женщин с хроническими вирусными инфекциями. Акушерство и гинекология. 2023; 12: 169-79. [Samarina A.V., Mozaleva O.L., Martirosian M.M., Skryabneva T.S., Shamaeva N.S., Filatova M.P. The use of a subcutaneous contraceptive implant in women with chronic viral infections. Obstetrics and Gynecology. 2023; (12): 169-79 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.295.
  74. Лекарственные взаимодействия, ресурс Университета Ливерпуль. Доступно по: https://hep-druginteractions.org/checker [University of Liverpool Interactions. Available at: https://hep-druginteractions.org/checker].

Received 11.11.2024

Accepted 20.11.2024

About the Authors

Maria I. Yarmolinskaya, Dr. Med. Sci., Professor of the Russian Academy of Sciences, Head of the Department of Gynecology and Endocrinology, Head of the Center for Diagnostics and Treatment of Endometriosis, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Saint-Petersburg, Russia; Professor at the Department of Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia,
m.yarmolinskaya@gmail.com, Researcher ID: P-2183-2014, Scopus Author ID: 7801562649, SPIN: 3686-3605, https://orcid.org/0000-0002-6551-4147
Sergey V. Nedogoda, Dr. Med. Sci., Head of the Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education of Volgograd State Medical University, Ministry of Health of Russia, Volgograd, Russia, nedogodasv@mail.ru, Researcher ID: O-4656-2014, Scopus Author ID: 6507198479, SPIN: 7005-7846,
https://orcid.org/0000-0001-5981-1754
Sergey N. Avdeev, Dr. Med. Sci., Professor, Academician of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia, аvdeev_s_n@staff.sechenov.ru,
Researcher ID: G-6950-2015, Scopus Author ID: 7003292838, SPIN: 1645-5524, https://orcid.org/0000-0002-5999-2150
Natalya A. Tsareva, PhD, Associate Professor at the Department of Pulmonology, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia, +7(495)609-14-00, n_tsareva@mail.ru, Scopus Author ID: 967612, SPIN: 7722-8596,
https://orcid.org/0000-0001-9357-4924
Elena N. Andreeva, Dr. Med. Sci., Professor, Deputy Director of the Center – Head of the Institute of Reproductive Medicine, Head of the Department of Endocrine Gynecology, Endocrinology Research Center, Moscow, Russia; Professor at the Department of Reproductive Medicine and Surgery, Russian University of Medicine,
Moscow, Russia, endogin@mail.ru, Researcher ID: B-5889-2017, Scopus Author ID: 7102485410, SPIN: 1239-2937, https://orcid.org/0000-0002-5949-1815
Anna V. Samarina, Dr. Med. Sci., Professor at the Department of Socially Significant Infections and Phthisiopulmonology, Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia; Head of the Department of Maternity and Childhood, Center for the Prevention and Control of AIDS and Infectious Diseases, St. Petersburg, Russia, avsamarina@mail.ru, Researcher ID: B-1693-2018, Scopus Author ID: 36999474200, SPIN: 2878-7130, https://orcid.org/0000-0003-1438-2399
Elena L. Amelina, PhD, Head of the Cystic Fibrosis Department, Pulmonology Scientific Research Institute of Federal Medical and Biological Agency of Russia,
Moscow, Russia, +7(926)205-03-91, eamelina@mail.ru, Scopus Author ID: 7003985681, SPIN: 6341-4662, https://orcid.org/0000-0002-5356-9415
Irina V. Gubonina, PhD, Head of Gastroenterology Department, Scandinavia Clinic (AVA-PETER LLC), St. Petersburg, Russia, giv70@bk.ru, Author ID: 886213,
Scopus ID: 8262853500, SPIN: 4457-1730, https://orcid.org/0000-0002-6302-7767
Natalia I. Klimenchenko, PhD, Senior Researcher at the 1st Obstetric Department of Pregnancy Pathology, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia, natalite@list.ru, https://orcid.org/0000-0002-9901-225X

Similar Articles

№4 / 2017
Chuprynin V.D., Khilkevich E.G., Buralkina N.A., Melnikov M.V., Chursin V.V., Veredchenko A.V., Saiddanesh Sh.F.
A general surgeon’s opinion about surgical treatment for deeply infiltrating endometriosis
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.